Making it Possible
Envision a world where progressive myopia is a thing of the past.
With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.
Making it Possible
Envision a world where progressive myopia is a thing of the past.
With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.
Latest News
Eyenovia to present at two upcoming investor conferences
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer and John Gandolfo, Eyenovia’s Chief Financial Officer, are scheduled to present at the 21st Annual H.C. Wainwright 21stAnnual Global Investment Conference being held on September 8-10, 2019 and the Ladenburg Thalmann 2019 Healthcare Conference being held on September 24, 2019 in New York. Read More
A Transformative Biopharmaceutical Company
Eyenovia is a clinical stage, ophthalmic biopharmaceutical company that is transforming therapies primarily for the treatment of progressive myopia, presbyopia, and improving diagnostic eye exams. We believe our breakthrough technology enables these first-in-class microdosed therapies that are designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing drugs.
See How We Make it Possible
Vision
VISION, our phase III NDA enabling study for the temporary improvement in sight for adults with presbyopia
is scheduled to enroll and complete in 2020.
More information coming soon!
These results showed the efficacy and safety of the fixed combination microdose formulation and the potential for offices to improve their patient flow. Eyenovia expects to file the NDA for its MicroStat product in 2020.
